High Complete-Response Rates, Thin Safety Detail, Tough Competition: Celldex’s CSU Readout

Barzolvolimab met every Phase 3 CSU goal, with 42–54% complete responses. Shares still fell on high expectations, thin safety detail, and oral/injectable rivals.